← Back to Search

Virus Therapy

NPC-21 Low dose for Cytomegalovirus

Phase 2

Waitlist Available

Research Sponsored by Nobelpharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 weeks

Awards & highlights

Study Summary

This trial is testing a drug to prevent CMV infection in people who are getting a kidney transplant from a donor who has CMV.

Eligible Conditions

Cytomegalovirus (CMV)

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Amount of CMV DNA

Changes in EQ-5D-5L score from Baseline

Incidence and duration of anti-CMV therapy during the Rescue Phase

+6 more

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: NPC-21 Low doseExperimental Treatment1 Intervention

NPC-21 (Low dose) will be administered

Group II: NPC-21 High doseExperimental Treatment1 Intervention

NPC-21 (High dose) will be administered

Group III: NPC-21 PlaceboPlacebo Group1 Intervention

Placebo (normal saline) will be administered

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

NPC-21 High dose

2020

Completed Phase 2

~90

NPC-21 Low dose

2020

Completed Phase 2

~90

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NobelpharmaLead Sponsor

34 Previous Clinical Trials

2,090 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned NPC-21 Low dose for public use?

"On a safety scale from 1 to 3, NPC-21 Low dose scored 2 due to existing clinical evidence for its security; however, no data exists yet confirming its efficacy."

Answered by AI

Are participants who are over thirty-five years old eligible for this research?

"Based on the parameters outlined in this trial's entry requirements, participants must not be younger than 18 and should not exceed 76 years of age."

Answered by AI

Are any individuals currently being recruited to participate in this research?

"Per clinicaltrials.gov, this medical trial is currently not seeking patients for enrollment. The protocol was first published on June 1st 2020 and last updated October 14th 2022. Notwithstanding, there are 54 other trials actively recruiting participants right now."

Answered by AI

Who is eligible for enrollment in this research experiment?

"This medical experiment allows 108 individuals, between 18 and 76 years of age, suffering from cytomegalovirus to take part. Criteria for eligibility includes: the ability to complete a kidney transplant as per institutional standards; seronegativity pre-transplantation; having received or scheduled to receive a first kidney transplant from CMV seropositive donor within 7 days prior to drug administration."

Answered by AI

How many sites are overseeing this research project?

"Recruitment for this clinical trial is underway in 13 distinct medical centres, such as The Christ Hospital based in Cincinnati and the University of Michigan located in Ann Arbor. Additionally Washington University School of Medicine is also participating with 10 other sites enrolling patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

2020. "A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04225923.